Nuvalent reports Q1 2023 net loss of $25.2M; NVL-655 Phase 1 data expected H2 2023

Nuvalent, Inc.

2023-Q1 EPS reported -$0.44

Net loss of $25.2M ($0.44 per share) for Q1 2023.
Cash, cash equivalents and marketable securities of $450.5M; runway into H2 2025.
R&D expenses $22.1M, G&A expenses $8.1M for Q1 2023.
Preliminary dose-escalation data for NVL-655 (ALK inhibitor) from ALKOVE-1 trial expected H2 2023.
NVL-520 (ROS1) Phase 1 enrollment ongoing; NVL-330 (HER2) in IND-enabling studies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nuvalent, Inc. reported the first quarter of 2023 results: net income Net loss for the first quarter of 2023 was $25.2 million, EPS $0.44 per share.

Period: the first quarter of 2023
Net income: Net loss for the first quarter of 2023 was $25.2 million
EPS: $0.44 per share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2023 was $25.2 million, or $0.44 per share.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvalent, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020806

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.